Additive effects of antiepileptic drugs and pentylenetetrazole on hearing

被引:14
|
作者
Nekrassov, Vladimir [1 ]
Sitges, Maria [1 ]
机构
[1] Univ Nacl Autonoma Mexico, Inst Invest Biomed, Depto Biol Celular & Fisiol, Mexico City 04510, DF, Mexico
关键词
audition; BAEPs; carbamazepine; epilepsy; phenytoin; vinpocetine; valproic acid;
D O I
10.1016/j.neulet.2006.07.042
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The long-term effect of three of the most widely used antiepileptic drugs at relevant doses on the hearing decline that accompanies pentylenetetrazole (PTZ)-induced experimental epilepsy was investigated here, and compared with the effect of vinpocetine (VPC), which is a drug with antiepileptic potential. For this purpose, cortical activity (monitored by the EEG) and auditory sensitivity, as indicated by brainstem. auditory evoked potential (BAEP) threshold at 4 and 8 kHz tone frequencies, were determined in guinea pigs daily injected for 28 days with vehicle (control), 20 mg/kg carbamazepine (CBZ), 6 mg/kg phenytoin (PHT), 30 mg/kg valproate (VPA) or 2 mg/kg vinpocetine (VPC) before and after the administration of PTZ at a convulsing dose (100 mg/kg). Results show that all the antiepileptic drugs tested were more or less effective in preventing PTZ-induced seizures. The long-term treatment with VPC decreased the auditory threshold, whereas the long-term treatment with CBZ, PHT or VPA increased the auditory threshold to a similar extent as the convulsing agent, PTZ. The combined effects of the antiepileptic drugs and PTZ on auditory threshold were additive. Therefore, only VPC prevented the increase in the auditory threshold induced by PTZ. It is concluded that the hearing loss produced by the long-term treatment with the most commonly used antiepileptic drugs could be aggravated by the illness. The prevention exerted by VPC on the hearing decline that accompanies experimental epilepsy, along with its capacity to control seizures at low doses in this and other animal models of epilepsy, would make VPC a valid candidate for the treatment of epilepsy. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:276 / 280
页数:5
相关论文
共 50 条
  • [1] Additive effects of antiepileptic drugs and pentylenetetrazole on hearing
    Nekrassov, V
    Sitges, M.
    JOURNAL OF NEUROCHEMISTRY, 2007, 102 : 294 - 294
  • [2] Additive effects of antiepileptic drugs and pentylenetetrazole on hearing
    Nekrassov, V.
    Sitges, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 92 - 92
  • [3] EFFECTS OF ANTIEPILEPTIC DRUGS ON PENTYLENETETRAZOLE-INDUCED EPILEPTIFORM ACTIVITY IN THE INVITRO HIPPOCAMPUS
    PIREDDA, S
    YONEKAWA, W
    WHITTINGHAM, TS
    KUPFERBERG, HJ
    EPILEPSIA, 1986, 27 (04) : 341 - 346
  • [4] Synergistic and additive effects of antiepileptic drugs in epileptic patients
    Froscher, W
    3RD EUROPEAN CONGRESS OF EPILEPTOLOGY, 1998, : 387 - 393
  • [5] Response to sertraline and antiepileptic drugs in pentylenetetrazole kindling in rats
    Hussain, Md
    Rashid, Haroon
    Katyal, Jatinder
    BRAIN RESEARCH, 2021, 1771
  • [6] Antiepileptic effects of NPY on pentylenetetrazole seizures
    Woldbye, DPD
    REGULATORY PEPTIDES, 1998, 75-6 : 279 - 282
  • [7] ANTIEPILEPTIC EFFECTS OF QUININE IN THE PENTYLENETETRAZOLE MODEL OF SEIZURE
    Torabinejad, B.
    Nassiri-Asl, M.
    Zamansoltani, F.
    EUROPEAN PSYCHIATRY, 2011, 26
  • [8] Antiepileptic effects of quinine in the pentylenetetrazole model of seizure
    Nassiri-Asl, Marjan
    Zamansoltani, Farzaneh
    Torabinejad, Behnam
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2009, 18 (02): : 129 - 132
  • [9] Amlodipine enhances the activity of antiepileptic drugs against pentylenetetrazole-induced seizures
    Kaminski, RM
    Mazurek, M
    Turski, WA
    Kleinrok, Z
    Czuczwar, SJ
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2001, 68 (04) : 661 - 668
  • [10] Influence of sildenafil on the anticonvulsant activity of some antiepileptic drugs in the pentylenetetrazole test in mice
    Nieoczym, Dorota
    Socala, Katarzyna
    Luszczki, Jarogniew J.
    Czuczwar, Stanislaw J.
    Wlaz, Piotr
    PHARMACOLOGICAL REPORTS, 2012, 64 (01) : 239 - 241